Enterin
2014
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$16.7M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displaces α-synuclein aggregates and restores normal signaling between the gut and the brain, enabling patients with Parkinson's disease and other neurodegenerative conditions to have a better the quality of life.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- 2005 Market Street
- Suite 3125
- Philadelphia, PA 19103
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Enterin’s full profile, request a free trial.
Enterin Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 28-Jan-2019 | $16.7M | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 2. Early Stage VC (Series A2) | 10-Jul-2017 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Enterin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A-2 | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A-1 | 2,846,620 | $0.000100 | 5% | $2.91 | $2.91 | 1x | $2.91 | 12.23% |
Enterin Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| New Ventures Funds | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |
Enterin Executive Team (4)
Enterin Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Jay Brammer | Enterin | Board Member | 000 0000 | |
| Mark Finn | New Ventures Funds | Board Member | 000 0000 | |
| Michael Zasloff Ph.D | Enterin | Co-Founder, Chairman & Chief Executive Officer | 000 0000 | |
| Richard Propper MD | Enterin | Board Member | 000 0000 |